Neoantigen Peptide Manufacturing Market to Record an Exponential CAGR by 2030
16 Jun 2022
VaccineCell TherapyImmunotherapyAcquisitionCollaborate
JERSEY CITY, N.J., June 16, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "
Global Neoantigen Peptides Manufacturing Market
by Scale of operations (Research/Preclinical, Clinical, Commercial), by End-Users (Pharmaceutical/Vaccine developers companies, Contract Research Organizations (CRO), Academic and Research Institutes) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
According to the latest research by InsightAce Analytic, the global Neoantigen Peptides Manufacturing market is expected to grow with CAGR of 16.4% during the forecast period of 2022-2030.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1270
Neoantigen peptides are derived from the somatic mutation of a specific tumour. These peptides are used to activate the immune system of a cancer cell. In manufacturing neoantigen-based vaccines, personalized neoantigen peptides are synthesized, which helps induce the T-cell population. T-Cell Receptors(TCRs) recognize the HLA molecule on which neoantigen peptides are bound during the synthesis. Neoantigens are a recognized model of cancer vaccine delivery, and other types of immunotherapy are being studied to treat many types of cancer.
Advancements in neoantigen production algorithms will consistently produce peptides for cancer research and drug development. Significant market factors of the Neoantigen peptide manufacturing are an increased number of favourable clinical trials, a rise in cancer and chronic disease cases, and the need for sustainable treatments for such diseases. In addition, biotechnology research advancements will enhance the study of personalized neoantigen peptides. External funding for cancer medicines' research and development also pushes the market upward.
However, the market will be limited by the higher costs of designing and developing personalized cancer therapeutics and delayed clinical trials due to COVID-19's impact. Reduced process time and cost, treatment gaps, partnerships and collaboration between various healthcare stakeholders, and data analytics are expected to create growth opportunities for the neoantigen production market. Compared to Asia and Europe, North America dominates the market, leading to rapid research and development, rising cancer incidence and a growing need for improved treatment procedures.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1270
Major key players operating in the neoantigen peptide manufacturing market are CPC Scientific Inc, Polypeptide group, Genscript Biotech, Kaneka Eurogentec S.A., Vivitide, Almac, BCN Peptides, Creative Peptides, Pepscan, Provepharm, Creosalus, Gyros Protein Technologies, Other Prominent Players.
Key Developments In The Market:
In Mar 2022, Pepscan announced that its specialists would manufacture the personalized peptide pools to treat cancer patients in Evaxion's phase IIb trial. Evaxion Biotech, a clinical-stage biotechnology company, recently published the initial results of the peptide-based personalized therapy EVX-01 in patients with metastatic melanoma. Pepscan had provided the personalized peptide pools for its phase I/IIa trial.
In Apr 2020, GenScript company announced the commercial launch of its neoantigen peptide synthesis service for personalized cancer therapeutics. GenScript partnered with several T-cell therapy and personalized cancer vaccine companies to develop the infrastructure for reliably manufacturing complex peptides for its neoantigen peptide synthesis platform.
In Feb 2019, CPC Scientific Inc., a leading global CDMO specializing in synthetic peptide manufacturing, announced today that they would manufacture GMP-grade neoantigen peptides for investigators at UNC Lineberger Comprehensive Cancer Center (LCCC) for individualized immunotherapy. CPC Scientific will supply GMP-grade neoantigen peptides, the sequences of which will be determined via genomics and bioinformatics, for use in the LCCC therapeutic neoantigen vaccine program.
In Jan 2019, Almac group (CDMO)added a second stream for high output GMP peptide manufacture to its facility in Edinburgh, Scotland. The site manufactures Neoantigen-derived peptides to produce its personalized cancer vaccines.
Market Segments
Global Neoantigen Peptides Manufacturing Market, by
Scale of operations, 2020-2030 (Value US$ Mn)
Research/Preclinical
Clinical
Commercial
Global Neoantigen Peptides Manufacturing Market, by
End-users 2020-2030 (Value US$ Mn)
Pharmaceutical/Vaccine developers companies
Academic and research institutes
Global Neoantigen Peptides Manufacturing Market, by
Region, 2020-2030 (Value US$ Mn)
North America
Europe
Latin America
Middle East & Africa
North America Neoantigen Peptides Manufacturing Market, by
Country, 2020-2030 (Value US$ Mn)
U.S.
Canada
Europe Neoantigen Peptides Manufacturing Market, by
Country, 2020-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific Neoantigen Peptides Manufacturing Market, by
Country, 2020-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand
Latin America Neoantigen Peptides Manufacturing Market, by
Country, 2020-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America
Middle East & Africa Neoantigen Peptides Manufacturing Market, by
Country, 2020-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa
For Customization @: https://www.insightaceanalytic.com/customisation/1270
Other Related Reports Published by InsightAce Analytic:
Global Peptide CDMO (Pharmaceutical) Market
Global Neoantigen Cancer Vaccine Market
Global Protein Design and Engineering Market
Global Next-Generation Biomanufacturing Market
Global Biopharmaceutical Excipient Manufacturing Market
Global mRNA Synthesis and Manufacturing Services Market
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Neoantigen Peptides Manufacturing market
To receive an industry overview and future trends of the Neoantigen Peptides Manufacturing market
To analyze the Neoantigen Peptides Manufacturing market drivers and challenges
To get information on the Neoantigen Peptides Manufacturing market size (Value US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Neoantigen Peptides Manufacturing market industry
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
SOURCE InsightAce Analytic Pvt. Ltd.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.